TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Open-label, Multicentre, 12 Month Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5mg) in Patients With Choroidal Neovascularisation Secondary to Pathological Myopia (PM)
Brief Summary: This study is designed to provide efficacy and safety data in patients with choroidal neovascularisation (CNV) secondary to myopia using an individualized as-needed (PRN) dosing schedule. Eligible patients who have provided written agreement to take part in the study will receive an intravitreal (into the study eye) injection of ranibizumab 0.5mg. Following eye examinations and tests at monthly clinic visits, the study doctor will repeat the injections on a monthly basis as required for an additional 11 months, in accordance with specified retreatment criteria.

Patients will be in the study for approximately 12 months and will visit the hospital clinic 14 times over that period. The main assessments will include visual acuity tests, eye examinations, optical coherence tomography (OCT) to assess retinal thickness, fundus photography and fluorescein angiography (FA), measurement of intraocular pressure, blood pressure and pulse measurements and completion of health-related questionnaires'.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
B: Arm Label: Ranibizumab driven by disease activity; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Arm Label: Ranibizumab driven by stabilization criteria; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Arm Label: Verteporfin PDT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Verteporfin PDT, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT | Intervention Type: DRUG; Name: Verteporfin PDT; Assigned to Arm(s): Verteporfin PDT | Intervention Type: DRUG; Name: Sham Ranibizumab; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT | Intervention Type: DRUG; Name: Sham verteporfin PDT; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: ranibizumab 0.5mg; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab 0.5mg | Intervention Type: DRUG; Name: ranibizumab 0.5mg; Assigned to Arm(s): ranibizumab 0.5mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to see whether turmeric can be effective in treatment of pruritus in hemodialysis patients.


Options:
A: Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin 75mg daily for 12 weeks | Arm Label: fexofenadine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fexofenadine 60 mg daily for 12 weeks | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin 75mg daily for 12 weeks; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: fexofenadine 60 mg daily for 12 weeks; Assigned to Arm(s): fexofenadine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Senna; Type: ACTIVE_COMPARATOR; Interventions: Drug: Senna | Intervention Type: DRUG; Name: Senna; Assigned to Arm(s): Senna | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ergocalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50,000 Units Ergocalciferol | Arm Label: oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 50,000 Units Ergocalciferol; Assigned to Arm(s): Ergocalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): oral placebo
D: Arm Label: turmeric; Type: EXPERIMENTAL; Interventions: Drug: turmeric | Arm Label: plasebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: turmeric; Assigned to Arm(s): turmeric | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): plasebo | Intervention Type: DRUG; Name: turmeric; Assigned to Arm(s): turmeric

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Familias Unidas Stage III Study: Preventing Substance Abuse in Hispanic Youth
Brief Summary: The focus of this study will be to test the Familias Unidas Intervention program among Hispanic 8th graders in the Miami-Dade County Public School System. This study will contribute to the advancement of knowledge in both the scientific community and the Hispanic population in Miami-Dade County. It will shed light on whether and to what extent Familias Unidas is effective in preventing drug use and unsafe sexual behavior in Hispanic adolescents. To the scientific community, the investigators will disseminate our findings via peer-reviewed publications and presentations at scientific meetings.

The design for the proposed study is a randomized controlled trial. This design is considered the "gold standard" design when evaluating the efficacy of two (or more) treatment conditions. Participants for this study will be 744 Hispanic 8th grade adolescents and their parents recruited from 24 randomly selected middle schools in Miami Dade County that meet the school inclusion/exclusion criteria. A total of 12 schools (for a total of 372 Hispanic adolescents and their parents) will be randomized to Familias Unidas and a total of 12 schools (for a total of 372 Hispanic adolescents and their parents) will be randomized to the Community Practice.


Options:
A: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Communities That Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communities That Care | Intervention Type: BEHAVIORAL; Name: Communities That Care; Assigned to Arm(s): Communities That Care Intervention
B: Arm Label: Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Intervention Type: BEHAVIORAL; Name: Family-Skills Training; Assigned to Arm(s): Control Group, Intervention Group
C: Arm Label: Family Function Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Familias Unidas | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Familias Unidas; Assigned to Arm(s): Family Function Intervention
D: Arm Label: 1) MI/Family Check-Up; Type: EXPERIMENTAL; Interventions: Behavioral: MI/Family Check-up | Arm Label: 2) MI only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MI only | Intervention Type: BEHAVIORAL; Name: MI/Family Check-up; Assigned to Arm(s): 1) MI/Family Check-Up | Intervention Type: BEHAVIORAL; Name: MI only; Assigned to Arm(s): 2) MI only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients With Advanced NSCLC
Brief Summary: The main purpose of this study is to compare two types of treatment-standard palliative care (which usually is given towards the end of life) and integrated palliative care (which is given soon after diagnosis) to see which is better for improving quality of life of participants with advanced non-small cell lung cancer. Palliative care is care that tries to lessen the symptoms of a disease. Although many people with advanced lung cancer receive palliative care or hospice toward the end of their disease, the entire course of their disease is often complicated by physical and emotional difficulties. Palliative care may be useful when it is started soon after diagnosis.


Options:
A: Arm Label: Standard Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Palliative Care Group | Arm Label: Integrated Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated Palliative Care Intervention | Intervention Type: OTHER; Name: Standard Palliative Care Group; Assigned to Arm(s): Standard Palliative Care Group | Intervention Type: OTHER; Name: Integrated Palliative Care Intervention; Assigned to Arm(s): Integrated Palliative Care Group
B: Arm Label: ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: ramucirumab, Other: Best Supportive Care (BSC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: ramucirumab; Assigned to Arm(s): ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo, ramucirumab
C: Arm Label: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab (IMC-1211B) DP, Drug: Paclitaxel | Arm Label: Placebo and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Ramucirumab (IMC-1211B) DP; Assigned to Arm(s): Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo and Paclitaxel, Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: TS-1 and cisplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: TS-1 | Intervention Type: DRUG; Name: TS-1 and cisplatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: TS-1; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients With Advanced NSCLC
Brief Summary: The main purpose of this study is to compare two types of treatment-standard palliative care (which usually is given towards the end of life) and integrated palliative care (which is given soon after diagnosis) to see which is better for improving quality of life of participants with advanced non-small cell lung cancer. Palliative care is care that tries to lessen the symptoms of a disease. Although many people with advanced lung cancer receive palliative care or hospice toward the end of their disease, the entire course of their disease is often complicated by physical and emotional difficulties. Palliative care may be useful when it is started soon after diagnosis.


Options:
A: Arm Label: Early entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early palliative care intervention | Arm Label: Later entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Later entry group | Intervention Type: BEHAVIORAL; Name: Later entry group; Assigned to Arm(s): Later entry group | Intervention Type: BEHAVIORAL; Name: Early palliative care intervention; Assigned to Arm(s): Early entry group
B: Arm Label: Specialised palliative care (SPC) group; Type: EXPERIMENTAL; Interventions: Other: Specialised palliative care (SPC) | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Specialised palliative care (SPC); Assigned to Arm(s): Specialised palliative care (SPC) group
C: Arm Label: Early Palliative Care Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Arm Label: Conventional Cancer Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Intervention Type: BEHAVIORAL; Name: Early Palliative Care Referral; Assigned to Arm(s): Conventional Cancer Care, Early Palliative Care Referral
D: Arm Label: Standard Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Palliative Care Group | Arm Label: Integrated Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated Palliative Care Intervention | Intervention Type: OTHER; Name: Standard Palliative Care Group; Assigned to Arm(s): Standard Palliative Care Group | Intervention Type: OTHER; Name: Integrated Palliative Care Intervention; Assigned to Arm(s): Integrated Palliative Care Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients With Advanced NSCLC
Brief Summary: The main purpose of this study is to compare two types of treatment-standard palliative care (which usually is given towards the end of life) and integrated palliative care (which is given soon after diagnosis) to see which is better for improving quality of life of participants with advanced non-small cell lung cancer. Palliative care is care that tries to lessen the symptoms of a disease. Although many people with advanced lung cancer receive palliative care or hospice toward the end of their disease, the entire course of their disease is often complicated by physical and emotional difficulties. Palliative care may be useful when it is started soon after diagnosis.


Options:
A: Arm Label: Specialised palliative care (SPC) group; Type: EXPERIMENTAL; Interventions: Other: Specialised palliative care (SPC) | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Specialised palliative care (SPC); Assigned to Arm(s): Specialised palliative care (SPC) group
B: Arm Label: Early palliative care consultation; Type: EXPERIMENTAL; Interventions: Other: Early palliative care consultation | Arm Label: Care as usual; Type: OTHER; Interventions: Other: Care as usual | Intervention Type: OTHER; Name: Early palliative care consultation; Assigned to Arm(s): Early palliative care consultation | Intervention Type: OTHER; Name: Care as usual; Assigned to Arm(s): Care as usual
C: Arm Label: Interventional arm; Type: EXPERIMENTAL; Interventions: Other: Interventional arm: Early best palliative care | Arm Label: Standard arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Interventional arm: Early best palliative care; Assigned to Arm(s): Interventional arm
D: Arm Label: Standard Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Palliative Care Group | Arm Label: Integrated Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated Palliative Care Intervention | Intervention Type: OTHER; Name: Standard Palliative Care Group; Assigned to Arm(s): Standard Palliative Care Group | Intervention Type: OTHER; Name: Integrated Palliative Care Intervention; Assigned to Arm(s): Integrated Palliative Care Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran
Brief Summary: Fibromyalgia Syndrome (FMS) afflicts 2% of the U.S. population and have huge individual and societal costs in terms of quality of life, social and work functioning, health care use, and lost productivity. Although single therapy approaches such as medication, graduated exercise, and Cognitive Behavioral Therapy (CBT) are well-established treatment approaches, the majority of FMS continue to report significant levels of pain and pain-related disability. Testing the efficacy of using combination therapies such and CBT with medication has considerable potential to maximize treatment response. Also, exploring the biological and psychological mechanisms underlying combination treatment may pave the way for developing new treatments for FMS sufferers.

We chose to study drug and CBT for several reasons: 1) the scarcity of trials that manipulate medications along with CBT in FMS, 2) the prohibitive nature of adding an exercise treatment arm in a study that has both time and budgetary constraints, 3) the complexity in understanding the mechanism of actions of 3 different modes of intervention in one clinical trial, and 4) the desire to explore mechanisms in this program of research, in particular the potential effects of a biological intervention (drug) on what is traditionally considered a psychological outcome (pain-related attributions and cognition) and the potential effects of a psychological intervention (CBT) on what is traditionally considered a physiological outcome (pain sensitivity).


Options:
A: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran 100mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Milnacipran 100mg; Assigned to Arm(s): Milnacipran
C: Intervention Type: DRUG; Name: milnacipran hydrochloride; Assigned to Arm(s): N/A
D: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of A3309, an Ileal Bile Acid Transport Inhibitor, on Gastrointestinal and Colonic Motor Functions in Female Patients With Functional Constipation
Brief Summary: This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in patients with functional constipation.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 4
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2
C: Arm Label: A3309 15 mg; Type: EXPERIMENTAL; Interventions: Drug: A3309 | Arm Label: A3309 20 mg; Type: EXPERIMENTAL; Interventions: Drug: A3309 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: A3309; Assigned to Arm(s): A3309 15 mg, A3309 20 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 72 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 145 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 290 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 579 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: linaclotide acetate; Assigned to Arm(s): 145 ug linaclotide acetate, 290 ug linaclotide acetate, 579 ug linaclotide acetate, 72 ug linaclotide acetate | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): Matching Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trials of Diet and Lifestyle Intervention to Promote Chinese Postpartum Women's Health
Brief Summary: Previous studies have shown "Doing the month", a traditional practice for postpartum women in China and other Asian countries, may be associated with higher prevalence of postpartum problems. The current multicenter randomized controlled trial (RCT) aims to evaluate outcomes of diet and lifestyle interventions in Chinese postpartum women.


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: moderate exercise and healthy, low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate exercise and healthy, low-fat diet; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Diet | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Diet and Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Diet and Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): Diet | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Diet and Exercise; Assigned to Arm(s): Diet and Exercise
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
D: Arm Label: Diet and Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Diet and Lifestyle Intervention in Chinese Postpartum Women | Intervention Type: BEHAVIORAL; Name: Diet and Lifestyle Intervention in Chinese Postpartum Women; Assigned to Arm(s): Diet and Lifestyle counseling

Answer: D